Epidermal growth factor receptor (EGFR) mutations account for 15–25% of non-small cell lung cancer (NSCLC), and EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib provide significant clinical benefit and improved progression-free survival (PFS) for these patients. Here, EGFR is linked to non-small cell lung carcinoma.